Technical Analysis for ZYNE - Zynerba Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 11.87 1.63% 0.19
ZYNE closed up 1.63 percent on Thursday, July 18, 2019, on 68 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ZYNE trend table...

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
NR7 Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish 1.63%
Fell Below 50 DMA Bearish 1.63%
Expansion Pivot Sell Setup Bearish Swing Setup 1.63%
Wide Range Bar Range Expansion 1.63%
Below Lower BB Weakness 1.63%

Older signals for ZYNE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates, including ZYN002 and ZYN001, which represent cannabinoid therapeutics for several indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In preclinical animal studies, ZYN002's permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. ZYN001 is a pro-drug of delta-9-tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. In preclinical animal studies, ZYN001 demonstrated effective skin permeation with sustained delivery and rapid conversion of ZYN001 to THC.
Pharmaceutical Pain Drugs Chemical Compounds Osteoarthritis Psychoactive Drugs Entheogens Cannabidiol Cannabinoids Fibromyalgia Fragile X Syndrome
Is ZYNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.47
52 Week Low 2.75
Average Volume 2,065,733
200-Day Moving Average 7.752
50-Day Moving Average 13.2616
20-Day Moving Average 13.635
10-Day Moving Average 13.849
Average True Range 1.0294
ADX 20.58
+DI 16.513
-DI 26.1844
Chandelier Exit (Long, 3 ATRs ) 12.6091
Chandelier Exit (Short, 3 ATRs ) 14.5882
Upper Bollinger Band 15.6402
Lower Bollinger Band 11.6298
Percent B (%b) 0.06
BandWidth 29.412541
MACD Line -0.0082
MACD Signal Line 0.318
MACD Histogram -0.3262
Fundamentals Value
Market Cap 157.36 Million
Num Shares 13.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -4.57
Price-to-Sales 0.00
Price-to-Book 1.77
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.98
Resistance 3 (R3) 12.98 12.61 12.80
Resistance 2 (R2) 12.61 12.33 12.61 12.73
Resistance 1 (R1) 12.24 12.15 12.06 12.24 12.67
Pivot Point 11.87 11.87 11.78 11.87 11.87
Support 1 (S1) 11.50 11.59 11.32 11.50 11.07
Support 2 (S2) 11.13 11.41 11.13 11.01
Support 3 (S3) 10.76 11.13 10.95
Support 4 (S4) 10.76